Design, Synthesis, and Biological Evaluation of Potent and Selective Class IIa Histone Deacetylase (HDAC) Inhibitors as a Potential Therapy for Huntington’s Disease

Roland W. Bürli(Covance (United Kingdom)), Celia Dominguez(CHDI Foundation), Perla Breccia, George McAllister, Philip M. Leonard, Marieke Lamers, Vahri Beaumont(University of Bristol), Rebecca E. Jarvis, Julie Vann, Michel Maillard(CHDI Foundation), Alan F. Haughan, Ignacio Muñoz-Sanjuán(CHDI Foundation), Liz Stones, Christine M. Richardson, Hannah McNeil, Grant Wishart(Charles River Laboratories (United Kingdom)), Maria Beconi(CHDI Foundation), Kathy Lyons, John E. Mangette(Albany Molecular Research (United States)), Samantha Jane Hughes(University of Trás-os-Montes and Alto Douro), Andrew J. Stott, Kim L. Matthews, Ilka Müller, Christopher A. Luckhurst, Dawn Yates, Omar Aziz, Stephen D. Penrose, Catherine M. O’Connell(California Institute of Technology), Michael E. Wall(Los Alamos National Laboratory), Tania Mead
Journal of Medicinal Chemistry
November 21, 2013
Cited by 149


Related Papers